AstraZeneca antibody cocktail works against Omicron in study
Study was conducted by independent investigators of the US Food and Drug Administration
AstraZeneca (AZN.L) said on Thursday a lab-study of its COVID-19 antibody cocktail, Evusheld, found that the treatment retained neutralising activity against the Omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the US Food and Drug Administration, the company said, adding that more analyses of Evusheld against Omicron are being conducted by AstraZeneca and third-parties, with data expected "very soon".
For the latest news, follow us on Twitter @Aaj_Urdu. We are also on Facebook, Instagram and YouTube.
coronavirus
AstraZeneca
covid
Omicron
latest news
Related Stories
PM Shehbaz aims for a polio-free Pakistan, hails frontline workers
Coronavirus update from across Pakistan: 2 more deaths
Frequent power cuts torment China amid record heatwave
WHO turns to public for monkeypox name change
Two policemen guarding polio team killed in Khyber Pakhtunkhwa’s Tank
Novartis says lung cancer drug canakinumab fails another trial
Taboola
Taboola ads will show in this div
Most Popular
Comments are closed on this story.